sorry, we can't preview this file
...but you can still download rsob180132_si_002.docx
Supplementary Fig 2 from Reduced Interleukin-38 in non-small cell lung cancer is associated with tumour progression
journal contributionposted on 25.09.2018 by Feng Wang, Weihua Zhang, Tianfeng Wu, Heying Chu
Any type of content formally published in an academic journal, usually following a peer-review process.
Lung cancer continues to be the leading cause of cancer-related deaths worldwide due to its high incidence, malignant behaviour and lack of major advancements in treatment strategy. The occurrence and development of lung cancer is closely related to inﬂammation. Thus, we conducted the present study to investigate the effects of IL-38 (Interleukin 38), a newly identified anti-inflammatory factor, on non-small cell lung cancer (a novel prognostic indicator and non-small cell lung cancer (NSCLC)), which accounts for about 85% of all lung cancers. We first evaluated the IL-38 expression in 384 pairs of NSCLC samples and their adjacent normal mucosa by real-time PCR, ELISA (enzyme-linked immunoassay) and tissue microarrays. Then the role of IL-38 on patient survival rates, cancer progression and their sensitivity to chemotherapy drugs was assessed. IL-38 was barely expressed in the NSCLC tissues but highly expressed in the adjacent normal tissues. The downregulation of IL-38 was significantly correlated with the results of American Joint Committee on Cancer stage, differentiation and it was also shown to be an independent prognostic indicator of disease-free survival and overall survival for patients with NSCLC. Overexpression of IL-38 in NSCLC cells suppressed cell migration, invasion, proliferation, colony formation through suppressing β-catenin. IL-38 inhibited NSCLC formation in the mice model and sensitized the cancer cells to chemotherapy drugs. Our results showed that IL-38 plays an inhibitory role in NSCLC development and function as a novel prognostic indicator and a potential therapeutic target.